Bristol Myers Squibb is hoping that arlocabtagene autoleucel, its CAR-T cell therapy directed at GPRC5D, could provide a competitive boost over bispecific antibodies with the same target given its potentially lower incidence of on-target toxicities, which may boil down to differences between the two modalities.
ASH: Better Safety Could Boost BMS’s Anti-GPRC5D CAR-T
BMS presented Phase I data for arlocabtagene autoleucel, showing a strong median PFS and lower incidence and severity of trouble swallowing, a common side effect of anti-GPRC5D drugs.
More from Cell Therapies
More from Conferences
• By
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.